Contract Development Services

The companies will collaborate to produce and improve the recombinant properties of Aethlon’s Hemopurifier blood purification device.

The acquisition broadens the CDMO’s preclinical and clinical offering to include bioanalytical and drug discovery services.

Catalent Applied Drug Delivery Institute announced a partnership with Rutgers University to examine the challenges of pediatric drug formulation and delivery.

The new center will help biopharmaceutical and pharmaceutical manufacturers with product development.

Catalent expands the scope of the OptiForm Solution Suite to bridge gap from late-stage discovery to Phase I trials.

GE Healthcare’s Dharmacon business and CordenPharma contract manufacturing enter a strategic collaboration to accelerate the oligonucleotide development process.

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold?

Advances in process analytical technology have been achieved, but significant challenges remain.

A case study reviews the reformulation and scale up of high drug load prototype using wet granulation process for a model formulation.

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

The new facility will focus on formulation development, drug product analytical development, and quality control.

Saneca Pharma is making significant investment in its API capabilities to support client demand for smaller batch sizes and streamlined scale-up.

CPhI Pharma Awards seek nominations for excellence in development and manufacturing.

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

PharmSource report addresses how the opportunity for antibody drug conjugates measures up to the bio/pharma industry’s expectations.

Sustainable harvesting combined with CMO expertise helped Centroflora CMS ensure supply continuity after it acquired Boehringer Ingelheim's non-captive API phytochemicals portfolio.

Mergers and acquisitions have changed the shape of the contract services market as big players seek to build full-service capabilities.

For successful partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.

Novasep is building a new synthesis laboratory and adding capacity for kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials, at its Pennsylvania, US facility.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

A facility expansion adds space for production of Repligen’s tangential flow system.

Novasep has entered into an agreement with Celladon to provide scale-up and pre-validation studies for the drug substance for MYDICAR.

Protecting workers, patients, and the environment requires advanced technologies.

Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.

Annual study shows CMO technical expertise is not enough.

Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.

Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.

Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Experts from contract testing laboratories and service organizations shared their perceptions of analytical testing advances, and challenges still ahead.